Limertinib
Phase 2Small molecule
Limertinib is one of 12 small molecule programs targeting Carboplatin. It is currently in Phase 2.
1
Indications
3
Total Trials
3
Active Trials
11
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
14 competitors in Carboplatin
#DrugCompanyPhaseTrials
1Paraplatin
AAvyxa
Approved
Taxol
TevaPhase 3
Avastin
RochePhase 3
Herceptin
RochePhase 2
Zytiga
Johnson & JohnsonPhase 2
Jevtana
SanofiPhase 2
Perjeta
RochePhase 2
Rayos
RRoxane Laboratories
Phase 2
Serplulimab
Shanghai Henlius BiotechPhase 2
Ivonescimab /kg
JJiangsu Cancer Institute & Hospital
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
First-line Treatment1 trial
Carboplatin1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Limertinib. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- HHunan Province Tumor Hospital